INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Targeting Forkhead Box M1 (FOXM1) in Human Cancer

Show full item record

Bookmark or cite this item:

Files in this item

File Description Format
PDF Halasi_Marianna.pdf (2MB) Restricted Access (no description provided) PDF
Title: Targeting Forkhead Box M1 (FOXM1) in Human Cancer
Author(s): Halasi, Marianna
Advisor(s): Gartel, Andrei
Contributor(s): Gartel, Andrei; Tyner, Angela; Merrill, Bradley; Tonetti, Debra
Department / Program: Biochemistry and Molecular Genetics
Graduate Major: Biochemistry and Molecular Genetics
Degree Granting Institution: University of Illinois at Chicago
Degree: PhD, Doctor of Philosophy
Genre: Doctoral
Subject(s): FOXM1 DNA-damage proteasome inhibitor apoptosis ROS anticancer drugs Forkhead box M1 Reactive oxygen species
Abstract: Targeting Forkhead Box M1 (FOXM1) in Human Cancer Marianna Halasi Department of Biochemistry and Molecular Genetics University of Illinois at Chicago Chicago, Illinois (2012) Dissertation Chairperson: Pradip Raychaudhuri Forkhead Box M1 (FOXM1) is an oncogenic transcription factor of the Forkhead family with an important role in cell proliferation and cell cycle progression. However, in recent years it has become a significant factor in cancer development. To date published data support examining the potential of FOXM1 targeting. Our laboratory identified thiazole antibiotics as potent FOXM1 inhibitors. Investigation of the mechanism of action of these FOXM1 inhibitors revealed a novel positive autoregulation of FOXM1. We demonstrate that the thiopeptides exhibit proteasome inhibitory activity and that bona-fide proteasome inhibitors also inhibit FOXM1. We show that FOXM1/proteasome inhibitors efficiently downregulate the protein expression of FOXM1, induce cell death in cancer cells, and reduce tumor growth in xenograft models of human breast and pancreatic cancer. We also evaluated targeting FOXM1 in combination with DNA-damage and oxidative stress. We demonstrate that RNAi-mediated knockdown of FOXM1 sensitizes cancer cells to apoptosis induced by DNA-damaging agents and ROS inducers. Moreover, we show that combination of FOXM1/proteasome inhibitors and DNA-damaging agents or ROS inducers leads to potent apoptosis. We found that JNK activation and Bcl-2 downregulation after suppression of FOXM1 may be the underlying mechanism for the increased cell death following DNA-damage. In addition, we show evidence that FOXM1/proteasome inhibitors in combination with ROS inducers efficiently suppress the growth of breast tumor xenografts. Our findings provide compelling evidence that FOXM1 is a suitable target for single or combinatorial anticancer therapy.
Issue Date: 2012-12-10
Genre: thesis
Rights Information: Copyright 2012 Marianna Halasi
Date Available in INDIGO: 2012-12-10
Date Deposited: 2012-08

This item appears in the following Collection(s)

Show full item record


Country Code Views
United States of America 156
China 22
Germany 9
United Kingdom 9
Netherlands 5


My Account


Access Key